RINVOQ

Medicinal product

(Invented) name

RINVOQ

Active substance (s)

Upadacitinibas

Strength

45 mg

Pharmaceutical form

pailginto atpalaidavimo tabletės

Route (s) of administration

vartoti per burną

Legal status for supply

Receptinis

Narrow therapeutic index (NTI)

No

ATC code (s)

L04AF03, upadacitinib

Marketing authorisation holder

AbbVie Deutschland GmbH & Co. KG , Vokietija

Date of authorisation

2019-12-16

Date of renewal

Documents

Rinvoq mokomoji medziaga sveikatos prieziuros specialistams.pdf

Rinvoq paciento kortele.pdf

Search in EMA Europe

Stage

Registruotas

Controlled?

No

Controlled substance type

Legal basis

8(3)

Procedure number

Marketing authorisation procedure

Centrinė registracija

Qualitative and quantitative composition

Prolonged-release tablet	1 vnt.
Upadacitinibas	45 mg

Packages

PAKID	NPAKID	NPAKID-7	Pack type	Pack size	Type of packaging	Proposed dispensing/classification	Marketing authorisation no.	Supply status	From	To	Package is in foreign language	From	To	Mock-up
109028	95134	1095134	lizdinė plokštelė	N28		Receptinis	EU/1/19/1404/010	Netiekiama	-	-	No	-	-
109029	95135	1095135	buteliukas	N28		Receptinis	EU/1/19/1404/011	Netiekiama	-	-	No	-	-

Stadijos

Data	Stadija
2019-12-16	Registruotas